Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says

MT Newswires Live

昨天

Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.

Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.

Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.

It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.

The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2667487616"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667487616\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667487616?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-15 13:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667487616","market":"hk","top_or_hot":-1,"title":"Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Telix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTelix's EPS Forecasts Rise Around 9% for Fiscal 2027, Around 21% for Fiscal 2028 After Glioma Drug Approval, Jefferies Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-15 13:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/TLX.AU\">Telix Pharmaceuticals</a> (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.</p><p>Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.</p><p>Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.</p><p>It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.</p><p>The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2667487616","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667487616","pubTimestamp":1789450283,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Telix Pharmaceuticals  earnings per share  forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration  approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography  drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","PET.AU":"PHOSLOCK ENVIRONMENTAL TECHN","TLX.AU":"TELIX PHARMACEUTICALS LTD","BK7047":"环境与设施服务"},"translate_title":"杰富瑞表示，胶质瘤药物获批后，Telix 2027 财年每股收益预测将增长约 9%，2028 财年每股收益预测将增长约 21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TLX.AU":1,"PET.AU":1},"content_text":"Telix Pharmaceuticals (ASX:TLX) earnings per share (EPS) forecasts rose by around 9% in fiscal 2027 and around 21% in fiscal 2028 after securing US Food and Drug Administration (FDA) approval for its new drug application for Pixclara, according to a Monday note by Jefferies.Major changes to the forecasts include an assumption of US reimbursement approval and the beginning of material US sales from the start of fiscal 2027's second half.Pixclara is an amino acid positron emission tomography (PET) drug for imaging glioma, a type of brain tumor.It is indicated for use with PET to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and paediatric patients one month of age and older.The brokerage assigned a buy rating to Telix with a raised price target of AU$30 per share from AU$29.30.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}